Development of an inactivated vaccine candidate for SARS-CoV-2

Gao, Qiang, Bao, Linlin, Mao, Haiyan, Wang, Lin, Xu, Kangwei, Yang, Minnan, Li, Yajing, Zhu, Ling, Wang, Nan, Lv, Zhe, Gao, Hong, Ge, Xiaoqin, Kan, Biao, Hu, Yaling, Liu, Jiangning, Cai, Fang, Jiang, Deyu, Yin, Yanhui, Qin, Chengfeng, Li, Jing, Gong, Xuejie, Lou, Xiuyu, Shi, Wen, Wu, Dongdong, Zhang, Hengming, Zhu, Lang, Deng, Wei, Li, Yurong, Lu, Jinxing, Li, Changgui, Wang, Xiangxi, Yin, Weidong, Zhang, Yanjun, Qin, Chuan·2020·Science
DOI 10.1126/science.abc1932

Cited by (1,435)

Items 401–500 of 1,435

  1. Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
    David G. Alleva, Andrea R. Delpero, Melanie M. Scully, Sylaja Murikipudi, Ramya Ragupathy, Emma K. Greaves, Thillainaygam Sathiyaseelan, Jeffrey R. Haworth, Nishit J. Shah, Vidhya Rao et al. · 2021 · Vaccine
  2. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity
    Jitendra Kumar Chaudhary, Rohitash Yadav, Pankaj Kumar Chaudhary, Anurag Maurya, Nimita Kant, Osamah Al Rugaie, Hoineiting Rebecca Haokip, Deepika Yadav, Rakesh Roshan, Ramasare Prasad et al. · 2021 · Cells
  3. Harnessing the power of novel animal-free test methods for the development of COVID-19 drugs and vaccines
    François Busquet, Thomas Härtung, Giorgia Pallocca, Costanza Rovida, Marcel Leist · 2020 · Archives of Toxicology
  4. Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases
    Ziyang Xu, Ami R. Patel, Nicholas J. Tursi, Xizhou Zhu, Kar Muthumani, Daniel W. Kulp, David B. Weiner · 2020 · Frontiers in Medical Technology
  5. The impact of immuno-aging on SARS-CoV-2 vaccine development
    Jennifer R Connors, Matthew R. Bell, Jennifer Marcy, Michele A. Kutzler, Elias K. Haddad · 2021 · GeroScience
  6. Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages
    Pureum Lee, Chang-Ung Kim, Sang Hwan Seo, Doo‐Jin Kim · 2021 · Immune Network
  7. Development of a Colloidal Gold-Based Immunochromatographic Strip for Rapid Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
    Ge Li, Aiping Wang, Yumei Chen, Yaning Sun, Yongkun Du, Xun Wang, Peiyang Ding, Rui Jia, Yanwei Wang, Gaiping Zhang · 2021 · Frontiers in Immunology
  8. The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein
    Xuemin Chen, Christina A. Rostad, Larry J. Anderson, He-Ying Sun, Stacey A. Lapp, Kathy Stephens, Laila Hussaini, Theda Gibson, Nadine Rouphael, Evan J. Anderson · 2021 · Virology
  9. Insight into COVID-19's epidemiology, pathology, and treatment
    Abdelmohcine Aimrane, Mehdi Ait Laaradia, Denis Séréno, Pascale Perrin, Ahmed Draoui, Blaid Bougadir, Mohamed Hadach, Mustapha Zahir, Naı̈ma Fdil, Omar El Hiba et al. · 2022 · Heliyon
  10. Experimental Models for the Study of Central Nervous System Infection by SARS-CoV-2
    Inmaculada Sanclemente-Alamán, Lidia Moreno‐Jiménez, María Soledad Benito‐Martín, Alejandro Arturo Canales-Aguirre, Jordi A. Matías‐Guiu, Jorge Matías‐Guiu, Ulises Gómez‐Pinedo · 2020 · Frontiers in Immunology
  11. COVID‐19 and novel mRNA vaccines in pregnancy: an updated literature review
    E Joubert, AC Kekeh, CN Amin · 2021 · BJOG An International Journal of Obstetrics & Gynaecology
  12. Postbiotics as potential promising tools for SARS-CoV-2 disease adjuvant therapy
    Nader Khani, Roya Abedi Soleimani, Ghasem Noorkhajavi, Azar Abedi Soleimani, Amin Abbasi, Aziz Homayouni Rad · 2022 · Journal of Applied Microbiology
  13. Distribution of Droplets and Immune Responses After Aerosol and Intra-Nasal Delivery of Influenza Virus to the Respiratory Tract of Pigs
    Veronica Martini, M. Hinchcliffe, E. Blackshaw, M. Joyce, Adam Mcnee, P. Beverley, A. Townsend, R. Macloughlin, E. Tchilian · 2020 · bioRxiv
  14. Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak
    Zheng Zhang, Chen Ji, Junghao Wang, Qiao Gao, Zhujun Ma, Shurong Xu, Li Zhang, Jill Cai, Weichang Zhou · 2021 · Biotechnology Progress
  15. National Vaccination and Local Intervention Impacts on COVID-19 Cases
    Toni Toharudin, Resa Septiani Pontoh, Rezzy Eko Caraka, Solichatus Zahroh, Panji Kendogo, Novika Sijabat, Mentari Dara Puspita Sari, Prana Ugiana Gio, Mohammad Basyuni, Bens Pardamean · 2021 · Sustainability
  16. Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers
    Nasikarn Angkasekwinai, Jaturong Sewatanon, Suvimol Niyomnaitham, Supaporn Phumiamorn, Kasama Sukapirom, Sompong Sapsutthipas, Rujipas Sirijatuphat, Orasri Wittawatmongkol, Sansnee Senawong, Surakameth Mahasirimongkol et al. · 2022 · Vaccine X
  17. Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy
    Ming‐liang Ma, Dawei Shi, Yang Li, Wei Hong, Dan‐yun Lai, Jun‐biao Xue, He‐wei Jiang, Hainan Zhang, Huan Qi, Qingfeng Meng et al. · 2021 · Cell Discovery
  18. SARS-CoV-2 immunity in animal models
    Zhao Chen, Yaochang Yuan, Qing‐Tao Hu, Airu Zhu, Fenghua Chen, Shu Li, Xin Guan, Chao Lv, Tian Tang, Yiyun He et al. · 2024 · Cellular and Molecular Immunology
  19. Vulnerabilities of the SARS-CoV-2 Virus to Proteotoxicity — Opportunity for Repurposed Chemotherapy of COVID-19 Infection
    Maryam Al-Motawa, Hafsa Abbas, Patrick Wijten, Alberto de la Fuente, Mingzhan Xue, Naila Rabbani, Paul John Thornalley · 2020 · Frontiers in Pharmacology
  20. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments
    Gisela Canedo-Marroquín, Farides Saavedra, Catalina A. Andrade, Roslye V. Berríos-Rojas, Linmar Rodríguez‐Guilarte, María Cecilia Opazo, Claudia A. Riedel, Alexis M. Kalergis · 2020 · Frontiers in Immunology
  21. Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein
    Pui Wang, Siu-Ying Lau, Shaofeng Deng, Pin Chen, Bobo Wing-Yee Mok, Jinxia Zhang, Andrew Chak-Yiu Lee, Kwok‐Hung Chan, Rachel Chun-Yee Tam, Haoran Xu et al. · 2021 · Nature Communications
  22. Development of an Inactivated Vaccine against SARS CoV-2
    Shaikh Terkıs Islam Pavel, Hazel Yetişkin, Muhammet Ali Uygut, Ahmet Furkan Aslan, Günsu Aydın, Öznur İnan, Büşra Kaplan, Aykut Özdarendeli · 2021 · Vaccines
  23. Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview
    Omid Gholizadeh, Saman Yasamineh, Parya Amini, Hamed Afkhami, Abbasali Delarampour, Sama Akbarzadeh, Rasool Karimi Matloub, Mahlagha Zahedi, Parastoo Hosseini, Mehrnaz Hajiesmaeili et al. · 2022 · Virology Journal
  24. The Impact of Social Media on the Acceptance of the COVID-19 Vaccine: A Cross-Sectional Study from Saudi Arabia
    Adel M. Al Fatease, Ali Alqahtani, Khalid Mubarak Orayj, Sultan Mohammed Alshahrani · 2021 · Patient Preference and Adherence
  25. An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19
    Murat Topuzoğulları, Tayfun Acar, Pelin Pelit Arayıcı, Burcu Uçar, Erennur Ugurel, Emrah Şefik Abamor, Tülin Arasoğlu, Dilek Turgut‐Balik, Serap Derman · 2020 · TURKISH JOURNAL OF BIOLOGY
  26. An overview of key potential therapeutic strategies for combat in the COVID-19 battle
    Gaurav Das, Surojit Ghosh, Shubham Garg, Satyajit Ghosh, Aniket Jana, Ramkamal Samat, Nabanita Mukherjee, Rajsekhar Roy, Surajit Ghosh · 2020 · RSC Advances
  27. The Current Status of COVID-19 Vaccines
    Kenneth H. Lundstrom · 2020 · Frontiers in Genome Editing
  28. A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques
    Paul E. Harris, Trevor Brasel, Christopher Massey, C.v. Herst, Scott Burkholz, Peter M. Lloyd, Tikoes Blankenberg, Thomas M. Bey, Richard T. Carback, Thomas W Hodge et al. · 2021 · Vaccines
  29. Mucosal IgA response elicited by intranasal immunization of Lactobacillus plantarum expressing surface-displayed RBD protein of SARS-CoV-2
    Letian Li, Maopeng Wang, Jiayi Hao, Jicheng Han, Tingting Fu, Jieying Bai, Mingyao Tian, Ningyi Jin, Guangze Zhu, Chang Li · 2021 · International Journal of Biological Macromolecules
  30. An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
    Zezhong Liu, Wei Xu, Zhenguo Chen, Wangjun Fu, Wuqiang Zhan, Yidan Gao, Jie Zhou, Yunjiao Zhou, Jianbo Wu, Qian Wang et al. · 2021 · Protein & Cell
  31. Novel nanostructure-coupled biosensor platform for one-step high-throughput quantification of serum neutralizing antibody after COVID-19 vaccination
    Liping Huang, Ying Li, Changyou Luo, Youqian Chen, Nadia Touil, H. El Annaz, Shaoqi Zeng, Tang Dang, Jiawei Liang, Wenjun Hu et al. · 2021 · Biosensors and Bioelectronics
  32. Influence of Vaccination Characteristics on COVID-19 Vaccine Acceptance Among Working-Age People in Hong Kong, China: A Discrete Choice Experiment
    Kailu Wang, Eliza Lai‐Yi Wong, Annie Wai-Ling Cheung, Peter Sen-Yung Yau, Vincent CH Chung, Charlene Hoi-Lam Wong, Dong Dong, Samuel Yeung Shan Wong, Eng‐Kiong Yeoh · 2021 · Frontiers in Public Health
  33. Coronavirus vaccine trials have delivered their first results — but their promise is still unclear
    Ewen Callaway · 2020 · Nature
  34. Recent Advances in Crimean-Congo Hemorrhagic Fever Virus Detection, Treatment, and Vaccination: Overview of Current Status and Challenges
    Khursheed Muzammil, Saba Rayyani, Ahmed Abbas Sahib · 2024 · Biological Procedures Online
  35. Preparedness needs research: How fundamental science and international collaboration accelerated the response to COVID-19
    Cormac M. Kinsella, Pauline Dianne Santos, Ignacio Postigo-Hidalgo, Alba Folgueiras-González, Tim Casper Passchier, Kevin P. Szillat, Joyce Odeke Akello, Beatriz Álvarez‐Rodríguez, Joan Martí‐Carreras · 2020 · PLoS Pathogens
  36. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses
    Yongping Yang, Wei Shi, Olubukola M. Abiona, Alexandra F. Nazzari, Adam S. Olia, Li Ou, Emily Phung, Tyler Stephens, Yaroslav Tsybovsky, Raffaello Verardi et al. · 2021 · Vaccines
  37. VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants
    Wasim Aluísio Prates-Syed, Lorena C. S. Chaves, Karin P. Crema, Larissa Vuitika, Aline Aparecida de Lima Lira, Nelson Côrtes, Victor Kersten, Francisco Eduardo Gontijo Guimarães, Mohammad Sadraeian, Fernando Luís Barroso da Silva et al. · 2021 · Vaccines
  38. Accuracy of serological testing for SARS‐CoV‐2 antibodies: First results of a large mixed‐method evaluation study
    Daniel Brigger, Michael Peter Horn, Luke F. Pennington, Abigail E. Powell, Denise Siegrist, Benjamin Weber, Olivier B. Engler, Vanja Piezzi, Lauro Damonti, Patricia Iseli et al. · 2020 · Allergy
  39. COVID-19 therapy: What weapons do we bring into battle?
    Sinara Mônica Vitalino de Almeida, José Cleberson Santos Soares, Keriolaine Lima dos Santos, Josival Emanuel Ferreira Alves, Amélia Galdino Ribeiro, Íris Trindade Tenório Jacob, Cindy Juliane da Silva Ferreira, Jéssica Celerino dos Santos, Jamerson Ferreira de Oliveira, Luiz Bezerra de Carvalho et al. · 2020 · Bioorganic & Medicinal Chemistry
  40. Citation Network Analysis of the Novel Coronavirus Disease 2019 (COVID-19)
    Clara Martínez-Pérez, Cristina C. Alvarez-Peregrina, Cesar C. Villa-Collar, Miguel Ángel Sánchez‐Tena · 2020 · International Journal of Environmental Research and Public Health
  41. Lysine 164 is critical for SARS-CoV-2 Nsp1 inhibition of host gene expression
    Zhou Shen, Guangxu Zhang, Yilin Yang, Mengxia Li, Siqi Yang, Guiqing Peng · 2020 · Journal of General Virology
  42. Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein
    Ritesh Tandon, Dipanwita Mitra, Poonam C. Sharma, Martin G. McCandless, Stephen J. Stray, John T. Bates, Gailen D. Marshall · 2020 · Scientific Reports
  43. A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response
    Duško Lainšček, Tina Fink, Vida Forstnerič, Iva Hafner‐Bratkovič, Sara Orehek, Žiga Strmšek, Mateja Manček‐Keber, Peter Pečan, Hana Esih, Špela Malenšek et al. · 2021 · Vaccines
  44. Safety and immunogenicity of inactivated COVID‐19 vaccine in health care workers
    Saovanee Benjamanukul, Sasiwimon Traiyan, Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Natthinee Sudhinaraset, Nasamon Wanlapakorn, Yong Poovorawan · 2021 · Journal of Medical Virology
  45. Execution and Design of an Anti HPIV-1 Vaccine with Multiple Epitopes Triggering Innate and Adaptive Immune Responses: An Immunoinformatic Approach
    M. Naveed, Allah Rakha Yaseen, H. Khalid, U. Ali, A. Rabaan, M. Garout, Muhammad A. Halwani, A. Al Mutair, S. Alhumaid, Z. Al Alawi et al. · 2022 · Vaccines
  46. Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates
    J. Francica, Barbara Flynn, K. Foulds, Amy T. Noe, Anne P. Werner, Ian N. Moore, M. Gagne, T. Johnston, C. Tucker, Rachel L. Davis et al. · 2021 · bioRxiv
  47. What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective
    HU Ying-lian, Simiao Chen · 2021 · Journal of Travel Medicine
  48. The sprint to solve coronavirus protein structures — and disarm them with drugs
    Megan Scudellari · 2020 · Nature
  49. 2020 update on human coronaviruses: One health, one world
    Xinbin Zhao, Yuecheng Ding, Jing Du, Yubo Fan · 2020 · Medicine in Novel Technology and Devices
  50. Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses
    Patrick O’Connell, Yasser Ali Aldhamen · 2020 · Human Vaccines & Immunotherapeutics
  51. Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates
    Labanya Mukhopadhyay, Pragya Dhruv Yadav, Nivedita Gupta, Sreelekshmy Mohandas, Deepak Y. Patil, Anita Shete-Aich, Samiran Panda, Balram Bhargava · 2021 · The Indian Journal of Medical Research
  52. Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2
    Ling Zhu, Yong‐Qiang Deng, Rong-Rong Zhang, Zhen Cui, Chun-Yun Sun, Changfa Fan, Xiaorui Xing, Weijin Huang, Qi Chen, Na-Na Zhang et al. · 2020 · National Science Review
  53. A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge
    Wenwen Jiang, Li Shi, Lukui Cai, Xiaoyu Wang, Jingyan Li, Heng Li, Jiangli Liang, Qin Gu, Guang Ji, Jing Li et al. · 2021 · Cell Reports
  54. COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review
    Faizan Zarreen Simnani, Dibyangshee Singh, Ramneet Kaur · 2021 · 3 Biotech
  55. The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
    Yao Jiang, Qian Yun Wu, Peipei Song, Chongge You · 2022 · Frontiers in Medicine
  56. The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic
    Maria Karoliny da Silva Torres, Carlos David Araújo Bichara, Maria de Nazaré do Socorro de Almeida, Mariana Cayres Vallinoto, Maria Alice Freitas Queiroz, Izaura Maria Vieira Cayres Vallinoto, Eduardo José Melo dos Santos, Carlos Alberto Marques de Carvalho, Antônio Carlos Rosário Vallinoto · 2022 · Frontiers in Microbiology
  57. Recent developments in SARS‐CoV‐2 vaccines: A systematic review of the current studies
    Mona Sadeghalvad, Amir Hossein Mansourabadi, Maryam Noori, Seyed Aria Nejadghaderi, Masoomeh Masoomikarimi, Masoumeh Alimohammadi, Nima Rezaei · 2022 · Reviews in Medical Virology
  58. Neutralizing antibodies to SARS‐CoV‐2 variants of concern including Delta and Omicron in subjects receiving mRNA‐1273, BNT162b2, and Ad26.COV2.S vaccines
    George Fei Zhang, Wen Meng, Luping Chen, Ling Ding, Jian Feng, Joseph Pérez, Abid Ali, Shenyu Sun, Zhentao Liu, Yufei Huang et al. · 2022 · Journal of Medical Virology
  59. The intestinal microbiota and improving the efficacy of COVID-19 vaccinations
    Jiezhong Chen, Luis Vitetta, Jeremy David Henson, Sean Hall · 2021 · Journal of Functional Foods
  60. Fc gamma receptors: Their evolution, genomic architecture, genetic variation, and impact on human disease
    Sarah Frampton, Rosanna Smith, Lili Ferson, Jane Gibson, Edward J. Hollox, Mark Steven Cragg, Jonathan C. Strefford · 2024 · Immunological Reviews
  61. SARS-CoV-2 infection and stem cells: Interaction and intervention
    Fenggang Yu, Rufu Jia, Yongyong Tang, Jin Liu, Benjie Wei · 2020 · Stem Cell Research
  62. SARS-CoV-2 vaccine candidates in rapid development
    Li-Feng Li, Pengbo Guo, Xiaoman Zhang, Zhi-Dan Yu, Wan-Cun Zhang, Hui-Qing Sun · 2020 · Human Vaccines & Immunotherapeutics
  63. Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models
    Ze-Jun Wang, Huajun Zhang, Jia Lu, Kang-Wei Xu, Cheng Peng, Jing Hui Guo, Xiao-Xiao Gao, Xin Hua Wan, Wen-Hui Wang, Chao Shan et al. · 2020 · Emerging Microbes & Infections
  64. Single-Molecule FRET Imaging of Virus Spike–Host Interactions
    Maolin Lu · 2021 · Viruses
  65. Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments
    Sareh Pandamooz, Benjamin Jurek, Carl-Philipp Meinung, Zahra Baharvand, Alireza Sahebi Shahem-abadi, Silke Haerteis, Jaleel A. Miyan, James R. Downing, Mehdi Dianatpour, Afshin Borhani‐Haghighi et al. · 2021 · The Annual Review of Pharmacology and Toxicology
  66. Effectiveness of COVID‑19 vaccines and their challenges (Review)
    Gabriella Marfè, Stefania Perna, Arvind Kumar Shukla · 2021 · Experimental and Therapeutic Medicine
  67. A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations
    Lidan Hu, Jingmiao Sun, Yan Wang, Danny Junyi Tan, Zhongkai Cao, Langping Gao, Yuelin Guan, Xiuwei Jia, Jianhua Mao · 2023 · Vaccines
  68. SARS‐CoV‐2: Mechanism of infection and emerging technologies for future prospects
    Shiqin Li, Sijia Li, Cyrollah Disoma, Rong Zheng, Mei Ling Zhou, Aroona Razzaq, Pinjia Liu, Yuzheng Zhou, Zijun Dong, Ashuai Du et al. · 2020 · Reviews in Medical Virology
  69. Management of COVID-19: current status and future prospects
    Md Alamgir Kabir, Rajib Ahmed, Rasheduzzaman Chowdhury, Sheikh Muhammad Asher Iqbal, Ramasamy Paulmurugan, Utkan Demirci, Waseem Asghar · 2021 · Microbes and Infection
  70. A Comprehensive Overview on the Production of Vaccines in Plant-Based Expression Systems and the Scope of Plant Biotechnology to Combat against SARS-CoV-2 Virus Pandemics
    Manu Kumar, Nisha Kumari, Nishant Thakur, Shashi Kant Bhatia, Ganesh Dattatraya Saratale, Gajanan Sampatrao Ghodake, Bhupendra M. Mistry, Hemasundar Alavilli, D. S. Kishor, Xueshi Du et al. · 2021 · Plants
  71. Rapid Development of Analytical Methods for Evaluating Pandemic Vaccines: A Covid-19 Perspective
    Jeremy Baldwin, Sakshi Piplani, Isaac G. Sakala, Yoshikazu Honda‐Okubo, Lei Li, Nikolai Petrovsky · 2021 · Bioanalysis
  72. Multitargeted Molecular Dynamic Understanding of Butoxypheser Against SARS-CoV-2: An in Silico Study
    Shaban Ahmad, Nagmi Bano, Sahar Qazi · 2022 · Natural Product Communications
  73. Spike N354 glycosylation augments SARS-CoV-2 fitness for human adaptation through structural plasticity
    Pan Liu, Can Yue, Bo Meng, Tianhe Xiao, Sijie Yang, Shuo Liu, Fanchong Jian, Qianhui Zhu, Yuanling Yu, Yan-Yan Ren et al. · 2024 · National Science Review
  74. A Deep Learning Interpretable Model for Novel Coronavirus Disease (COVID-19) Screening with Chest CT Images
    Eri Matsuyama · 2020 · Journal of Biomedical Science and Engineering
  75. In silico Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19
    Andrés López‐Cortés, Patricia Guevara‐Ramírez, Nikolaos C. Kyriakidis, Carlos Barba‐Ostria, Ángela León Cáceres, Santiago Xavier Guerrero, Esteban Ortiz‐Prado, Cristian Robert Munteanu, Eduardo Tejera, Doménica Cevallos-Robalino et al. · 2021 · Frontiers in Pharmacology
  76. Virus‐Free and Live‐Cell Visualizing SARS‐CoV‐2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors
    Yali Zhang, Shaojuan Wang, Yangtao Wu, Wangheng Hou, Lunzhi Yuan, Chenguang Shen, Juan Wang, Jianghui Ye, Qingbing Zheng, Jian Ma et al. · 2020 · Small Methods
  77. Current progress and challenges in the design and development of a successful COVID-19 vaccine
    Tingting Li, Tianying Zhang, Ying Gu, Shaowei Li, Ningshao Xia · 2021 · Fundamental Research
  78. Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques
    Kevin R. Bewley, Karen E. Gooch, Kelly M. Thomas, Stéphanie Longet, Nathan R. Wiblin, Laura E. Hunter, Kin Chan, Phillip J. Brown, Rebecca A Russell, Catherine M. K. Ho et al. · 2021 · Science Advances
  79. The prevalence, predictors and outcomes of acute liver injury among patients with COVID‐19: A systematic review and meta‐analysis
    Harapan Harapan, Jonny Karunia Fajar, Supriono Supriono, Gatot Soegiarto, Laksmi Wulandari, Fiha Seratin, Nyoman Gede Prayudi, Dara Puspita Dewi, Maria Theresia Monica Elsina, Lasarus Atamou et al. · 2021 · Reviews in Medical Virology
  80. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection
    Patricia Pérez, Adrián Lázaro-Frías, Carmen Zamora, Pedro J. Sánchez‐Cordón, David Astorgano, Joanna Luczkowiak, Rafael Bastos Delgado, José M. Casasnovas, Mariano Estéban, Juan García‐Arriaza · 2022 · Frontiers in Immunology
  81. A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines
    Naru Zhang, Kangchen Li, Zezhong Liu, Kutty Selva Nandakumar, Shibo Jiang · 2022 · Viruses
  82. Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates
    Jesse H. Erasmus, Amit P. Khandhar, Alexandra C. Walls, Emily A. Hemann, Megan A. O’Connor, Patience Murapa, Jacob F. Archer, Shanna S. Leventhal, Jim Fuller, Thomas B. Lewis et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  83. Effectiveness and Efficacy of Vaccine on Mutated SARS-CoV-2 Virus and Post Vaccination Surveillance: A Narrative Review
    Ihsanul Hafiz, Didi Nurhadi Illian, Okpri Meila, Ahmad Rusdan Handoyo Utomo, Arida Susilowati, Ipanna Enggar Susetya, Desrita Desrita, Gontar Alamsyah Siregar, Mohammad Basyuni · 2022 · Vaccines
  84. Overview of the recent advances in porcine epidemic diarrhea vaccines
    Miaozhan Wei, Lan Chen, Rong Zhang, Ze Chen, Yan-Juan Shen, Bi-Jun Zhou, Kai-Gong Wang, Chun-Lan Shan, Erpeng Zhu, Zhentao Cheng · 2024 · The Veterinary Journal
  85. Automated detection of COVID-19 and pneumonia diseases using data mining and transfer learning algorithms with focal loss from chest X-ray images
    Rana Khattab, Islam R. Abdelmaksoud, Samir Mohamed Abdelrazek · 2024 · Applied Soft Computing
  86. Selection of animal models for COVID-19 research
    Suresh Kumar, Pardeep Kumar Yadav, Ramesh Srinivasan, Perumal Nagarajan · 2020 · VirusDisease
  87. Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate
    D. Patel, C. Field, K. M. Septer, D. Sim, Matthew J. Jones, T. Heinly, T. Vanderford, E. McGraw, T. Sutton · 2021 · Journal of Virology
  88. CRISPR/Cas System: A Potential Technology for the Prevention and Control of COVID-19 and Emerging Infectious Diseases
    Ronghua Ding, Jinzhao Long, Mingzhu Yuan, Yuefei Jin, Haiyan Yang, Mengshi Chen, Shuaiyin Chen, Guangcai Duan · 2021 · Frontiers in Cellular and Infection Microbiology
  89. Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19
    Yanghong Ni, Aqu Alu, Lei Hong, Yang Wang, Min Wu, Xiawei Wei · 2021 · Molecular Biomedicine
  90. Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions
    Marcel Renn, Eva Bartok, Thomas Zillinger, Gunther Hartmann, Rayk Behrendt · 2021 · Pharmacology & Therapeutics
  91. COVID-19 and X-linked agammaglobulinemia (XLA) – insights from a monogenic antibody deficiency
    Mark J. Ponsford, Benjamin M.J. Shillitoe, Ian Robert Humphreys, Andrew R. Gennery, Stephen R.A. Jolles · 2021 · Current Opinion in Allergy and Clinical Immunology
  92. Integrated histopathological, lipidomic, and metabolomic profiles reveal mink is a useful animal model to mimic the pathogenicity of severe COVID-19 patients
    Zhiqi Song, Linlin Bao, Wei Deng, Jiangning Liu, Ren ErJun, Qi Lv, Mingya Liu, Feifei Qi, Ting Chen, Ran Deng et al. · 2022 · Signal Transduction and Targeted Therapy
  93. Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine
    Shihao Zhou, Yuting Li, Ruyan Zhang · 2022 · Frontiers in Immunology
  94. Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives
    Qiugang Zhu, Yan Xu, Ting Wang, Feiting Xie · 2022 · Frontiers in Immunology
  95. Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152
    Brunda Ganneru, Harsh Jogdand, Vijaya Kumar Daram, Narasimha Reddy Molugu, Sai D. Prasad, Srinivas Vellimudu, Krishna M. Ella, Rajaram Ravikrishnan, Amit Awasthi, Jomy Jose et al. · 2020 · SSRN Electronic Journal
  96. COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants
    Rashed Noor, Saadia Shareen, Muntasir Billah · 2022 · Bulletin of the National Research Centre/Bulletin of the National Research Center
  97. Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine
    Rasoul Mirzaei, Rokhsareh Mohammadzadeh, Farzad Mahdavi, Fariba Badrzadeh, Sheida Kazemi, Mehdi Ebrahimi, fatemeh soltani, Sima Kazemi, Ali Salimi Jeda, Mohammad Darvishmotevalli et al. · 2020 · International Immunopharmacology
  98. Phototherapy as a Rational Antioxidant Treatment Modality in COVID-19 Management; New Concept and Strategic Approach: Critical Review
    Reem Hanna, Snehal Dalvi, Tudor Sălăgean, Ioana Roxana Bordea, Stefano Benedicenti · 2020 · Antioxidants
  99. Severe acute respiratory syndrome coronavirus‐2 natural animal reservoirs and experimental models: systematic review
    Salma N. Younes, Nadin Younes, Farah M. Shurrab, Gheyath K. Nasrallah · 2020 · Reviews in Medical Virology
  100. The role and uses of antibodies in COVID-19 infections: a living review
    David Oliver Scourfield, Sophie G. Reed, Max N. Quastel, Jennifer Alderson, Valentina M T Bart, Alicia Teijeira Crespo, Ruth E. Jones, Ellie Pring, Felix Clemens Richter, David Ahern et al. · 2021 · Oxford Open Immunology